Large pharma companies at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

19 large pharma companies are at ENA 2026 — 31 presentations on the program and 1 with a booth in the exhibit hall. Most represented: Astellas (3 on the program), Hanmi Pharmaceutical (3 on the program), Chia Tai Tianqing (2 on the program). 8 of them have their own page in this guide. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–15 of 19 organizations

Organization	ENA 2026 Attendance
Astellas Tokyo, Japan
astellas.com Large pharma Pharmaceutical company with marketed cancer drugs and a pipeline including KRAS inhibitors and degraders.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents ASP2453, a novel KRAS G12C inhibitor, shows potent anti-tumor activity in various KRAS G12C-mutated preclinical models including genetically engineered mouse model Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Characterization of KRAS-G12D ubiquitination and degradation by setidegrasib (ASP3082) and its combination potential in preclinical models Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs ASP5834, a novel pan-KRAS degrader, shows potent anti-tumor activity in KRAS mutant cancer models Drug design
Hanmi Pharmaceutical Seoul, South Korea
hanmi.co.kr Large pharma Pharmaceutical company with marketed medicines and an R&D pipeline in oncology, obesity and metabolic disease.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Structure-based optimization of orally bioavailable EP300-selective degraders Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Engineered p53 mRNA Analogs Restore Tumor Suppressor Function in TP53-Mutant Cancers Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Engineered STING mRNA Analog Enables Dual Antitumor Activity Through Immune Activation and Tumor-Intrinsic Signaling Targeted agents
Chia Tai Tianqing Lianyungang, China
cttq.com Large pharma Pharmaceutical company, part of Sino Biopharmaceutical, developing targeted cancer drugs including degraders and molecular glues.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Epigenetic modulators (HDAC Bromodomain modulators, EZH2) TQB3306: a second-generation menin-MLL inhibitor overcoming acquired MEN1 resistance with superior efficacy in acute leukemia models Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Novel fourth-generation ALK inhibitor TQB5410 demonstrates potent activity against ALK-positive cancer Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs TQB3142, a clinical-stage BCL-XL PROTAC, demonstrates robust in vivo antitumor activity and a favorable pharmacokinetic profile as a potential best-in-class therapeutic Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Preclinical activity of TQB3125, an orally bioavailable pan-RAS(ON) molecular glue for KRAS-mutant pancreatic cancer Drug design
Novartis Basel, Switzerland
novartis.com Large pharma Global pharmaceutical company with oncology medicines including radioligand therapies and targeted agents.	Talk Wed Nov 18 5:15–5:35pm Part of Workshop 2: Radiopharmaceuticals Implementing Radioligand Therapy early trials in the Real World: Site selection, Implementation, and Supply-Chain Challenges ADCs & radioligands Session Fri Nov 20 9:30–10:45am Workshop 8: Proximity inducers beyond current PROTACs Drug design Talk Fri Nov 20 9:30–9:35am Part of Workshop 8: Proximity inducers beyond current PROTACs Setting the scene: The new world of proximity inducing therapeutics Drug design
Bristol Myers Squibb Princeton, NJ
bms.com Large pharma Global pharmaceutical company with oncology medicines in immunotherapy, cell therapy and protein degradation.	Talk Fri Nov 20 3:45–3:55pm Part of Plenary Session 7: Proffered papers BMS-986500: A novel molecular glue degrader of Cyclin E1 with first-in-class potential for treating CCNE1-amplified cancers and overcoming CDK4/6 inhibitor resistance in HR+ breast cancer Drug design · Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Cancer Genomics Pathway Activity Inference Reveals Mechanistic Insights and Potential Therapeutic Vulnerabilities in MSS-CRC Molecular Subtypes Genomics
Celltrion Pharm Cheongju, South Korea
celltrionph.com Large pharma Drugmaker in the Celltrion group making chemical drugs and biosimilars, now developing antibody-drug conjugates.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates A novel dual-payload ADC platform that can offer synergistic antitumoral efficacy of MMAE while reducing undesired side effects ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates ‘CellPh-Linker Conjugation’: an engineering-free Fab-site selective ADC conjugation technology ADCs & radioligands
Eli Lilly Indianapolis, Indiana
lilly.com Large pharma Global pharmaceutical company; its oncology portfolio includes kinase inhibitors and antibody-drug conjugates in development.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preclinical characterization of LY4402289, a novel DLL3-targeting antibody drug conjugate (ADC) delivering a NAMPT inhibitor payload ADCs & radioligands Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Vepugratinib-induced receptor tyrosine kinase (RTK) rewiring sensitizes FGFR3-altered urothelial cancer cells to HER2-targeted therapies Targeted agents
Pfizer New York, New York
pfizer.com Large pharmaExhibitor Global pharmaceutical company whose oncology portfolio includes antibody-drug conjugates gained with Seagen.	Booth Exhibiting at Booth 26 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates PF‑08098488, A Novel CEACAM5-Targeting MMAE ADC with Optimized Engineered-Cysteine Sites Designed to Enhance Therapeutic Index, Demonstrates Potent Antitumor Activity in Preclinical Models ADCs & radioligands
Amgen Thousand Oaks, CA
amgen.com Large pharma Global biotechnology drugmaker with oncology medicines including bispecific T-cell engagers and the KRAS G12C inhibitor sotorasib.	Session Wed Nov 18 4:15–5:45pm Workshop 1: GLP-1 and Cancer Interface
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global pharmaceutical company with oncology medicines spanning targeted therapies, antibody-drug conjugates and immunotherapies.	Talk Thu Nov 19 5–5:20pm Part of Workshop 6: Tumour microenvironment Role of myeloid cells in tumour progression and drug resistance Immuno-oncology
Boehringer Ingelheim Ingelheim, Germany
boehringer-ingelheim.com Large pharma Pharmaceutical company with an oncology pipeline including HER2 and KRAS-pathway inhibitors and T-cell engagers.	Talk Thu Nov 19 5:40–6pm Part of Workshop 5: Managing Tox from early therapeutics Cytokine release syndrome are we over diagnosing and overtreating Early clinical
Daiichi Sankyo Tokyo, Japan
daiichisankyo.com Large pharma Pharmaceutical company known for antibody-drug conjugates such as trastuzumab deruxtecan.	Talk Fri Nov 20 10–10:15am Part of Workshop 7: Novel Methodologies & Endpoints in New Drug Development G-score, a new relevant endpoint in Phase 1 studies Early clinical
Dong-A ST Seoul, South Korea
donga-st.com Large pharma Pharmaceutical company developing new drugs, including targeted protein degraders for cancer.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC Targeted agents
Incyte Wilmington, Delaware
incyte.com Large pharma Biopharmaceutical company with marketed oncology and dermatology medicines, including ruxolitinib.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Association of ctDNA Dynamics and Tumor Mutational Profiles With Clinical Outcomes in Recurrent Metastatic Epithelial Ovarian Cancer Patients Treated With CDK2 inhibitor in INCB123667-101 Biomarkers
Jeil Pharmaceutical
jeilpharm.co.kr Large pharma Korean pharmaceutical company that sells medicines and develops new drugs, including cancer therapies.	Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies JP9441, a Novel SOS1 Inhibitor, Demonstrates Broad Activity across RAS-Driven Tumors and Synergistic Efficacy with KRAS Inhibitors Targeted agents